CDK4 and cancer: Furthermore, sensitive cancers invariably acquire resistance to CDK4/6 inhibition [86], such that CDK4/6i’s are only efficacious in combination with drugs that target other pathways on which cancer cells rely to escape CDK4/6 dependency [87, 88].